C2206

C2206 is an orally administered drug evaluated as a reference comparator in a phase 1 clinical study alongside JW0302, with the primary pharmacodynamic outcome being its effect on gastric acidity in healthy adult subjects. While details about its precise chemical identity and mechanism of action are not directly available from primary sources, its use as a reference drug and the pharmacodynamic profile measured (reduction in gastric acidity) suggest that it is likely a proton pump inhibitor or a drug with antisecretory action. No published evidence connects C2206 to cyproheptadine, MK-2206, or other well-known drugs; it appears to be an internal or region-specific reference compound used in South Korean clinical trials for acid suppression[2].